Gene · 3568
Papers2,231
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
21 to 40 of 2,231
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Precision medicine in asthma: endotype stratification, biomarker-guided biologics, and emerging therapeutic strategies. | Mol Biol Rep | 2026 | 42467299 | PubTator, text mining | PubMed |
| Efficacy and Safety of IL-4Rα and IL-5/IL-5R Targeted Biologic Therapies in Type 2 Inflammatory Airway Diseases: A Systematic Review and Meta-Analysis. | J Clin Med | 2026 | 42452466 | PubTator, text mining | PubMed |
| Hypereosinophilia With Pseudomonas aeruginosa Infection in Patients With Asthma on Anti-Inteleurkin-5 Biologics. | Chest | 2026 | 42419852 | PubTator, text mining | PubMed |
| New pharmaceutical options for patients with allergic and asthma-related diseases: Balancing effectiveness and safety in selection of specific therapies. | Ann Allergy Asthma Immunol | 2026 | 42419394 | PubTator, text mining | PubMed |
| Case Report: Benralizumab combined with a steroid-sparing strategy in a case of severe eosinophilic granulomatosis with polyangiitis. | Front Immunol | 2026 | 42389539 | PubTator, text mining | PubMed |
| Comparative real-world effectiveness and safety of benralizumab and two mepolizumab dosing regimens in eosinophilic granulomatosis with polyangiitis: a 24-month prospective single-center cohort study. | Front Immunol | 2026 | 42375373 | PubTator, text mining | PubMed |
| Biological functions and clinical efficacy of IL-5/IL-5Rα-targeted therapies across eosinophilia-associated diseases. | Front Immunol | 2026 | 42367766 | PubTator, text mining | PubMed |
| Hemodynamic improvement but worsening hypoxemia after balloon pulmonary angioplasty: severe eosinophilic asthma unmasked in CTEPH. | BMC Pulm Med | 2026 | 42351060 | PubTator, text mining | PubMed |
| Adhesion molecules and T cell imbalance in severe eosinophilic asthma: Insights from anti-IL-5R treatment. | Pulmonology | 2026 | 42324975 | PubTator, text mining | PubMed |
| Eosinophil-linked pulmonary circulation in EGPA Improves under anti-IL-5/R therapy: A longitudinal study. | Eur J Intern Med | 2026 | 42321133 | PubTator, text mining | PubMed |
| The Immune Architecture of Eosinophilic Esophagitis: Mechanisms, Therapeutic Targets, and Precision Management. | Immunotargets Ther | 2026 | 42238716 | PubTator, text mining | PubMed |
| Asthma exacerbation profile of benralizumab for severe eosinophilic asthma (the BenRex study): a multicentre, prospective cohort study. | Lancet Respir Med | 2026 | 42214402 | PubTator, text mining | PubMed |
| Neoplasm Adverse Events Associated With Anti-Type 2 Biologics: An FAERS Database Pharmacovigilance Analysis Study. | Cancer Med | 2026 | 42178747 | PubTator, text mining | PubMed |
| Transcriptomic profiling reveals immune pathway dysregulation and key interferon-responsive genes in Systemic Lupus Erythematosus. | Adv Protein Chem Struct Biol | 2026 | 42177068 | PubTator, text mining | PubMed |
| Paucity of type 2 cytokines and atypical IL-5 receptor alpha patterns during established eosinophilic inflammation in seasonal allergic rhinitis. | Acta Otolaryngol | 2026 | 42159314 | PubTator, text mining | PubMed |
| Dupilumab after sequential omalizumab and benralizumab failure in T2-high asthma-COPD overlap: A case report. | Allergol Immunopathol (Madr) | 2026 | 42115803 | PubTator, text mining | PubMed |
| Renal involvement in hypereosinophilic syndrome: a systematic review with narrative synthesis of pathology, diagnosis, and therapy. | Front Immunol | 2026 | 42112328 | PubTator, text mining | PubMed |
| Assessment of Inhaled Corticosteroid Adherence in Adults with Severe Asthma Receiving Biologic Therapy: A Retrospective Observational Study. | J Asthma Allergy | 2026 | 42109535 | PubTator, text mining | PubMed |
Predicting Clinical Response to Benralizumab Using CT Imaging: Prognostic CT Air-Trapping for the Early Identification of Benralizumab Responders Among Eosinophilic Asthma Patients (BenraliScan) Study. | Chest | 2026 | 42106061 | PubTator, text mining | PubMed |
| Mucus Plugging as a Treatable Trait Across the Asthma-COPD Spectrum: The Role of Type 2 Cytokine Blockade and Quantitative Imaging. | Biomedicines | 2026 | 42072432 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/3568/papers?page=2